Literature DB >> 17158760

Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line.

O Arroyo-Helguera1, B Anguiano, G Delgado, C Aceves.   

Abstract

This study analyzes the uptake and antiproliferative effect of two different chemical forms of iodine, iodide (I-) and molecular iodine (I2), in MCF-7 cells, which are inducible for the Na+/I- symporter (NIS) and positive for pendrin (PDS). The mouse fibroblast cell line NIH3T3 was used as control. Our results show that in MCF-7 cells, I- uptake is sustained and dependent on NIS, whereas I2 uptake is transient with a maximal peak at 10 min and a final retention of 10% of total uptake. In contrast, no I- was taken up by NIH3T3 cells, and although I2 was captured with the same time pattern as in MCF-7 cells, its uptake was significantly lower, and it was not retained within the cell. The uptake of I2 is independent of NIS, PDS, Na+, and energy, but it is saturable and dependent on protein synthesis, suggesting a facilitated diffusion system. Radioiodine was incorporated into protein and lipid fractions only with I2 treatment. The administration of non-radiolabeled I2 and 6-iodo-5-hydroxy-8,11,14-eicosatrienoic acid (6-iodolactone, an iodinated arachidonic acid), but not KI, significantly inhibited proliferation of MCF-7 cells. Proliferation of NIH3T3 cells was not inhibited by 20 microM I2. In conclusion, these results demonstrate that I2 uptake does not depend on NIS or PDS; they suggest that in mammary cancer cells, I2 is taken up by a facilitated diffusion system and then covalently bound to lipids or proteins that, in turn, inhibit proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158760     DOI: 10.1677/erc.1.01250

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  18 in total

1.  Antiproliferative/cytotoxic effects of molecular iodine, povidone-iodine and Lugol's solution in different human carcinoma cell lines.

Authors:  Harald Rösner; Wolfgang Möller; Sabine Groebner; Pompilio Torremante
Journal:  Oncol Lett       Date:  2016-07-05       Impact factor: 2.967

2.  TRPM7 is regulated by halides through its kinase domain.

Authors:  Haijie Yu; Zheng Zhang; Annette Lis; Reinhold Penner; Andrea Fleig
Journal:  Cell Mol Life Sci       Date:  2013-03-08       Impact factor: 9.261

3.  MCF-7 breast carcinoma cells express ryanodine receptor type 1: functional characterization and subcellular localization.

Authors:  Carlos Saldaña; Mauricio Díaz-Muñoz; Anaid Antaramián; Adriana González-Gallardo; Pablo García-Solís; Verónica Morales-Tlalpan
Journal:  Mol Cell Biochem       Date:  2008-12-04       Impact factor: 3.396

Review 4.  The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues.

Authors:  Carmen Aceves; Brenda Anguiano; Guadalupe Delgado
Journal:  Thyroid       Date:  2013-08       Impact factor: 6.568

5.  Iodine uptake and prostate cancer in the TRAMP mouse model.

Authors:  Paloma Olvera-Caltzontzin; Guadalupe Delgado; Carmen Aceves; Brenda Anguiano
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

6.  Potassium Iodide Nanoparticles Enhance Radiotherapy against Breast Cancer by Exploiting the Sodium-Iodide Symporter.

Authors:  Benjamin L Cline; Wen Jiang; Chaebin Lee; Zhengwei Cao; Xueyuan Yang; Shuyue Zhan; Harrison Chong; Tao Zhang; Zhaoguo Han; Xuedan Wu; Li Yao; Hui Wang; Weizhong Zhang; Zibo Li; Jin Xie
Journal:  ACS Nano       Date:  2021-10-25       Impact factor: 18.027

7.  Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).

Authors:  Carmen Aceves; Pablo García-Solís; Omar Arroyo-Helguera; Laura Vega-Riveroll; Guadalupe Delgado; Brenda Anguiano
Journal:  Mol Cancer       Date:  2009-06-06       Impact factor: 27.401

8.  Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response.

Authors:  Aisyah Elliyanti; Dewi Rusnita; Nita Afriani; Yayi Dwina Billianti Susanto; Veronica Y Susilo; Sri Setiyowati; Wirsma Arif Harahap
Journal:  Nucl Med Mol Imaging       Date:  2020-01-03

9.  Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection.

Authors:  Yunuen Alfaro; Guadalupe Delgado; Alfonso Cárabez; Brenda Anguiano; Carmen Aceves
Journal:  Mol Cancer       Date:  2013-05-24       Impact factor: 27.401

10.  Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine.

Authors:  Frederick R Stoddard; Ari D Brooks; Bernard A Eskin; Gregg J Johannes
Journal:  Int J Med Sci       Date:  2008-07-08       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.